Engineering Medicines To Improve Patient Care

Pipeline

Developing Best-In-Class Solutions for Patients

Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Our pipeline represents a patient-centric model of innovation, which leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus.

Viridian Therapeutics Pipeline - October 2022

Viridian Therapeutics Pipeline October 2022

Viridian Therapeutics Pipeline October 2022

 


VRDN-001

VRDN-001 is a monoclonal antibody that binds and blocks the IGF-1R signaling pathway with sub-nanomolar affinity. This mechanism of action is clinically and commercially validated for the treatment of TED. The company’s ongoing first clinical trial for VRDN-001 is a Phase 1/2 proof of concept study that includes multiple randomized, placebo-controlled cohorts of TED patients designed to assess the potential for VRDN-001 to provide rapid improvement of signs and symptoms of TED, including proptosis. The protocol for this trial allows for additional patient cohorts to assess differing treatment paradigms that may offer advantages over currently available therapies, and mitigate patient treatment burden. In August 2022, the Company announced positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with TED. Access the news release and data deck.

Scientific publications for VRDN-001 can be found here.

VRDN-002

VRDN-002 is a distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED. In August 2022, the Company reported data from a Phase 1 clinical trial of VRDN-002. Access the news release.

Scientific publications for VRDN-002 can be found here.

VRDN-003

Based on the strength of the initial clinical data of VRDN-001 and VRDN-002, Viridian has initiated a third development program for the treatment of TED. VRDN-003 is a monoclonal antibody that incorporates half-life extension technology into the sequence of VRDN-001, preserving the unique pharmacological attributes of VRDN-001 while adding the enhanced pharmacokinetics of VRDN-002. VRDN-003 is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED, and is in development as an alternative to VRDN-002; the Company plans to evaluate clinical data from the VRDN-002 and VRDN-003 programs in late 2023 to select one of the programs to advance into Phase 3 development starting in early 2024.

VRDN-004

VRDN-004 is a discovery-stage therapeutic antibody program for an undisclosed rare disease.  We believe there is a significant opportunity to provide a more convenient, better performing product versus the only approved therapeutic in this disease. We are currently evaluating lead molecules generated by our antibody discovery and engineering platform.

VRDN-005

VRDN-005 is a discovery-stage program for another undisclosed indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody.

Read about our approach here.